A C118T polymorphism of ERCC1 and response to cisplatin chemotherapy in patients with late-stage non-small cell lung cancer

Journal of Cancer Research and Clinical Oncology

Volumn 138, Issue 2, 2012, Pages 231-238

  Cheng, Jian ^a   Ha, Minwen ^a   Wang, Yadi ^a   Sun, Jing ^b   Chen, Junchen ^a   Wang, Yue ^a   Tong, Chunyan ^c  

^a JINZHOU MEDICAL UNIVERSITY   (China)

^b Affliated Hospital of Binzhou Medical University   (China)

^c DALIAN MEDICAL UNIVERSITY   (China)

Author keywords

Cisplatin; ERCC1; Non small cell lung cancer; Polymorphisms

Indexed keywords

CISPLATIN; CYSTEINE; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; NAVELBINE; PACLITAXEL; THREONINE; TUMOR MARKER;

ADULT; AGED; ALLELE; AMINO ACID SUBSTITUTION; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CODON; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENOTYPE; HUMAN; LONG TERM CARE; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REAL TIME POLYMERASE CHAIN REACTION; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE; TUMOR DIFFERENTIATION;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; COHORT STUDIES; DISEASE-FREE SURVIVAL; DNA-BINDING PROTEINS; ENDONUCLEASES; FEMALE; GENE FREQUENCY; GENOTYPE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; PACLITAXEL; POLYMORPHISM, SINGLE NUCLEOTIDE; REGRESSION ANALYSIS; TREATMENT OUTCOME; VINBLASTINE;

EID: 84857039539     PISSN: 01715216     EISSN: 14321335     Source Type: Journal    
DOI: 10.1007/s00432-011-1090-1     Document Type: Article

References (25)

1. Camps C, Sirera R, Iranzo V, Taron M, Rosell R (2007) Gene expression and polymorphisms of DNA repair enzymes: cancer susceptibility and response to chemotherapy. Clin Lung Cancer 8: 369-375 (Pubitemid 46924057)
2. Cortinovis D, Bidoli P, Zilembo N, Fusi A, Bajetta E (2008) Oxaliplatin doublets in non-small cell lung cancer: a literature review. Lung Cancer 60: 325-331
3. GoYn J, Lacchetti C, Ellis PM, Ung YC, Evans WK (2010) First-line systemic chemotherapy in the treatment of advanced non-small cell lung cancer: a systematic review. J Thorac Oncol 5: 260-274
4. Gurubhagavatula S, Liu G, Park S, Zhou W, Su L, Wain JC, Lynch TJ, Neuberg DS, Christiani DC (2004) XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with platinum chemotherapy. J Clin Oncol 22: 2594-2601 (Pubitemid 41103746)
5. Isla D, Sarries C, Rosell R, Alonso G, Domine M, Taron M, Lopez-Vivanco G, Camps C, Botia M, Nunez L, Sanchez-Ronco M, Sanchez JJ, Lopez-Brea M, Barneto I, Paredes A, Medina B, Artal A, Lianes P (2004) Single nucleotide polymorphisms and outcome in docetaxel-cisplatin-treated advanced non-small-cell lung cancer. Ann Oncol 15: 1194-1203 (Pubitemid 39199306)
6. Kirschner K, Melton DW (2010) Multiple roles of the ERCC1-XPF endonuclease in DNA repair and resistance to anticancer drugs. Anticancer Res 30: 3223-3232
7. Knipscheer P, Raschle M, Smogorzewska A, Enoiu M, Ho TV, Scharer OD, Elledge SJ, Walter JC (2009) The Fanconi anemia pathway promotes replication-dependent DNA interstrand cross-link repair. Science 326: 1698-1701
8. Kwon HC, Roh MS, Oh SY, Kim SH, Kim MC, Kim JS, Kim HJ (2007) Prognostic value of expression of ERCC1, thymidylate synthase, and glutathione S-transferase P1 for 5-Xuorouracil/oxaliplatin chemotherapy in advanced gastric cancer. Ann Oncol 18: 504-509 (Pubitemid 46359630)
9. Li Y, Gu S, Wu Q, Li Y, Fu X, Mao Y, Huang Y, Xie Y (2007) No association of ERCC1 C8092A and T19007C polymorphisms to cancer risk: a meta-analysis. Eur J Hum Genet 15: 967-973 (Pubitemid 47308473)
10. Matakidou A, el Galta R, Webb EL, Rudd MF, Bridle H, Eisen T, Houlston RS (2007) Genetic variation in the DNA repair genes is predictive of outcome in lung cancer. Hum Mol Genet 16: 2333-2340 (Pubitemid 47423899)
11. Ohe Y, Ohashi Y, Kubota K, Tamura T, Nakagawa K, Negoro S, Nishiwaki Y, Saijo N, Ariyoshi Y, Fukuoka M (2007) Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan. Ann Oncol 18: 317-323 (Pubitemid 46323100)
12. Olaussen KA, Dunant A, Fouret P, Brambilla E, Andre F, Haddad V, Taranchon E, Filipits M, Pirker R, Popper HH, Stahel R, Sabatier L, Pignon JP, Tursz T, Le Chevalier T, Soria JC (2006) DNA repair by ERCC1 in non-small-cell lung cancer and cisplatinbased adjuvant chemotherapy. N Engl J Med 355: 983-991 (Pubitemid 44343542)
13. Park DJ, Zhang W, Stoehlmacher J, Tsao-Wei D, Groshen S, Gil J, Yun J, Sones E, Mallik N, Lenz HJ (2003) ERCC1 gene polymorphism as a predictor for clinical outcome in advanced colorectal cancer patients treated with platinum-based chemotherapy. Clin Adv Hematol Oncol 1: 162-166
14. Parkin DM, Bray FI, Devesa SS (2001) Cancer burden in the year 2000. The global picture. Eur J Cancer 37: S4-S66
15. Parkin DM, Bray F, Ferlay J, Pisani P (2005) Global cancer statistics, 2002. CA Cancer J Clin 55: 74-108 (Pubitemid 40372904)
16. Rosell R, Lord RV, Taron M, Reguart N (2002) DNA repair and cisplatin resistance in non-small-cell lung cancer. Lung Cancer 38: 217-227 (Pubitemid 35341796)
17. Schiller JH (2002) Small cell lung cancer: deWning a role for emerging platinum drugs. Oncology 63: 105-114
18. Shimizu J, Horio Y, Osada H, Hida T, Hasegawa Y, Shimokata K, Takahashi T, Sekido Y, Yatabe Y (2008) mRNA expression of RRM1, ERCC1 and ERCC2 is not associated with chemosensitivity to cisplatin, carboplatin and gemcitabine in human lung cancer cell lines. Respirology 13: 510-517 (Pubitemid 351725293)
19. Sorenson CM, Eastman A (1988) Mechanism of cis-diamminedichloroplatinum ( II)-induced cytotoxicity: role of G2 arrest and DNA double-strand breaks. Cancer Res 48: 4484-4488
20. SteVensen KD, Waldstrom M, Jeppesen U, Brandslund I, Jakobsen A (2008) Prediction of response to chemotherapy by ERCC1 immunohistochemistry and ERCC1 polymorphism in ovarian cancer. Int J Gynecol Cancer 18: 702-710 (Pubitemid 352020157)
21. Su D, Ma S, Liu P, Jiang Z, Lv W, Zhang Y, Deng Q, Smith S, Yu H (2007) Genetic polymorphisms and treatment response in advanced non-small cell lung cancer. Lung Cancer 56: 281-288 (Pubitemid 46590484)
22. Takenaka T, Yano T, Kiyohara C, Miura N, Kouso H, Ohba T, Kometani T, Shoji F, Yoshino I, Maehara Y (2010) EVects of excision repair cross-complementation group 1 (ERCC1) single nucleotide polymorphisms on the prognosis of non-small cell lung cancer patients. Lung Cancer 67: 101-107
23. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92: 205-216
24. Tibaldi C, Giovannetti E, Vasile E, Mey V, Laan AC, Nannizzi S, Di Marsico R, Antonuzzo A, Orlandini C, Ricciardi S, Del Tacca M, Peters GJ, Falcone A, Danesi R (2008) Correlation of CDA, ERCC1, and XPD polymorphisms with response and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients. Clin Cancer Res 14: 1797-1803 (Pubitemid 351469466)
25. Viguier J, Boige V, Miquel C, Pocard M, Giraudeau B, Sabourin JC, Ducreux M, Sarasin A, Praz F (2005) ERCC1 codon 118 polymorphism is a predictive factor for the tumor response to oxaliplatin/5-Xuorouracil combination chemotherapy in patients with advanced colorectal cancer. Clin Cancer Res 11: 6212-6217 (Pubitemid 41262950)